Products

  Products
Unique site-specific dual-payload glycan conjugation platform

About antibody-drug conjugates (ADC)

Antibody-drug conjugates (ADCs) are a class of therapeutics, in which the drugs can be attached to the antibody through specific linkers and conjugation methods.

References
  1. Carter PJ et al. Cancer J. 2008;14(3):154-169.
  2. Senter PD. Curr Opin Chem Biol. 2009;13(3):235-244. 3. Polson AG et al. Cancer Res. 2009;69(6):2358
Products

Unique Conjugation Technology

Products HoneyBear Biosciences' proprietary conjugation belongs to the new generation of site-specific conjugation technology. The core technology utilizes glycan conjugation.

SpecificityAdvantage
Precisely Conjugation site and conjugation ratioEfficacy, stability and safety increase
No antibody sequence mutation is neededTime and cost effective
Can Conjugate Two different payloadsWider application, efficacy and response rate increase, resistance decrease
ADC products are more homogeneousEfficacy, stability and safety increase
Exhibit high yield conjugation with easily purifiedTime and cost effective

Products

Facile dual-payload synthesis

Products
Combination of Different MOA Payloads

Enhance Efficacy; Decrease Resistance; Stimulate Immune Response

Different MOA Payloads
  • Tubulin inhibitor; DNA binder; Topo-I inhibitor
  • Different Agents
  • Radioisotope; protein degrader; immune modulator

CO-NECTAR™ Unique site-specific dual-payload glycan conjugation platform


Leveraging on HoneyBear’s Technologies to Revolutionize Next Generation ADC

1. Facile dual payload synthesis sets high barriers to entry
2. Dual payload concepts address multiple medical challenges that single payload ADCs current face
  • Low response rate
  • Short duration of response 
  • Resistance
3. Dual payload technologies enable attacking tumor at multiple fronts
  • Different yet complementary Mechanism of Action
  • Additive or synergistic effects
  • Induce endogenous anti-cancer immune response to achieve long term remission
4. First-in-class and Best-in-class warrant enormous market potentials

HoneyBear’s patented CO-NECTAR™

 
Products
Products

US11085062B2

Products

JP06888764B2

Products

CA3048452C

Products

AU201717388556B2

Products

TWI673363B

Products

KR2294517B1

Patent : Process For Preparing Glycoprotein-Drug Conjugates 
  • Anticipated expiration: 2037-12-29
  • Priority Date: US Provisional 62/440075, 29 Dec. 2016
  • WO2018126092A1, EP3568161A4, CN110121365A (OA)